Roche unveils long-term data from pivotal spinal muscular atrophy trial
Biogen and Novartis have previously rolled out long-term data with their respective spinal muscular atrophy therapies Spinraza and Zolgensma. Now, Roche is seeking to catch up with four-year data for its blockbuster risdiplam, aka Evrysdi.
Presenting at the Muscular Dystrophy Association Clinical and Scientific Conference, the pharma giant’s subsidiary Genentech unveiled positive data Monday in patients ages 2 to 25 from the SUNFISH pivotal study that had either type 2 or type 3 SMA. In short, Genentech said that its spinal muscular atrophy drug showed continued efficacy in patients four years after starting the therapy.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters